🔎 Trials Near Me

Home › Cancro metastatico › California › Los Angeles

Studi clinici su Cancro metastatico a Los Angeles, CA

57 studi su Cancro metastatico cercano partecipanti presso sedi a Los Angeles e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.

Testo ufficiale dello studio (inglese)

Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

In reclutamentoFase 2
  • The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles
  • Cedars-Sinai Medical Center, Los Angeles
Tutte le età · Tutti i sessi · Aggiornato il 5 ott 2026 · NCT05564377

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

In reclutamentoFase 1
  • UCLA Department of Medicine-Hematology/Oncology, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06465069

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

In reclutamentoFase 1/2
  • UCLA Jonsson Comprehensive Cancer Center, Los Angeles
  • USC Norris Comprehensive Cancer Center, Los Angeles
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

In reclutamentoFase 1
  • Cedars-Sinai Medical Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06234605

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

In reclutamentoFase 1
  • University of California - Los Angeles, Los Angeles
Età 19 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06586957

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

In reclutamentoFase 1
  • University of California Los Angeles, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06625775

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

In reclutamentoFase 2/3
  • Norris Comprehensive Cancer Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT06943755

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

In reclutamentoFase 1/2
  • Children's Hospital Los Angeles, Los Angeles
  • University of California at Los Angeles, Los Angeles
Fino a 25 anni · Tutti i sessi · Aggiornato il 25 set 2026 · NCT04094610

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

In reclutamentoFase 2/3
  • Cedars-Sinai Cancer at Cedars-Sinai Medical Center, Los Angeles
  • UCLA Department of Medicine - Hematology/Oncology, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06989437

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

In reclutamentoFase 3
  • Oncura Health - Good Samaritan, Los Angeles
  • California Research Institute, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07222566

Intratumoral N17350 in Advanced Solid Tumors

In reclutamentoFase 1/2
  • The Angeles Clinic and Research Institute, Los Angeles
  • UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT07339176

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

In reclutamentoFase 1
  • USC Norris Comprehensive Cancer Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT06915753

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

In reclutamentoFase 3
  • UCLA Hematology/Oncology - Westwood (Building 100), Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07213804

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

In reclutamentoFase 3
  • TRIO-US (Translational Research in Oncology-US), Los Angeles
  • UCLA Hematology/Oncology - Santa Monica, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07218380

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

In reclutamentoFase 3
  • USC/Norris Comprehensive Cancer Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07174336

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

In reclutamentoFase 1/2
  • UCLA Hematology & Oncology ( Site 0003), Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT06863272

CREO - Microwave Ablation Feasibility Study

In reclutamento
  • Cedars Sinai, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT07817147

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

In reclutamentoFase 1/2
  • Clinical Study Site, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT07335497

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

In reclutamentoFase 1
  • USC/Norris Comprehensive Cancer Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2026 · NCT06440005

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

In reclutamentoFase 3
  • Cedars-Sinai Medical Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06119581

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

In reclutamentoFase 1/2
  • Avenzo Therapeutics Recruiting Site, Los Angeles
  • Avenzo Therapeutics Recruiting Site, Los Angeles
Età da 18 a 75 · Tutti i sessi · Aggiornato il 4 set 2026 · NCT07038343

A Study of IDP-001 in Advanced or Metastatic Solid Tumors

In reclutamentoFase 1/2
  • START Los Angeles, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07602842

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

In reclutamentoFase 3
  • Los Angeles Cancer Network, Los Angeles
  • Cedars-Sinai Cancer at Cedars-Sinai Medical Facility, Los Angeles
  • Los Angeles Cancer Network_Century City, Los Angeles
  • e altri 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 set 2026 · NCT06072612

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

In reclutamentoFase 1
  • The Angeles Clinic, Los Angeles
  • UCLA, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 set 2026 · NCT04913285

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

In reclutamentoFase 2
  • University of California Los Angeles, Los Angeles
  • Samuel Oschin Cancer Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 21 ago 2026 · NCT06769698

FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3

In reclutamentoFase 1
  • University of California, Los Angeles (UCLA) - Division of Hematology-Oncology, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 ago 2026 · NCT05614739

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

In reclutamentoFase 2
  • Research Site, Los Angeles
Età da 18 a 130 · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT06792695

FOG-001 in Locally Advanced or Metastatic Solid Tumors

In reclutamentoFase 1/2
  • University of California, Los Angeles (UCLA), Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT05919264

A Study of MGC026 in Participants With Advanced Solid Tumors

In reclutamentoFase 1
  • The Angeles Clinic and Research Institute, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 11 ago 2026 · NCT06242470

A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors

In reclutamentoFase 1
  • START Los Angeles, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 ago 2026 · NCT06880549

Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes

In reclutamentoFase 1
  • Los Angeles General Medical Center, Los Angeles
  • USC / Norris Comprehensive Cancer Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 ago 2026 · NCT05687110

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

In reclutamentoFase 1
  • Keck Medicine of USC Koreatown, Los Angeles
  • Los Angeles General Medical Center, Los Angeles
  • USC / Norris Comprehensive Cancer Center, Los Angeles
Età 12 e oltre · Tutti i sessi · Aggiornato il 31 lug 2026 · NCT05372640

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

In reclutamentoFase 1/2
  • USC Norris Comprehensive Cancer Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 lug 2026 · NCT04657068

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

In reclutamentoFase 1/2
  • The Angeles Clinic and Research Institute, Los Angeles
Età 12 e oltre · Tutti i sessi · Aggiornato il 14 lug 2026 · NCT05533697

A Study of PYX-201 in Advanced Solid Tumors

In reclutamentoFase 1
  • Ronald Reagan UCLA Medical Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 giu 2026 · NCT05720117

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

In reclutamentoFase 1
  • Cedars-Sinai Medical Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 giu 2026 · NCT07458347

REMASTer: REcurrent Brain Metastases After SRS Trial

In reclutamento
  • UCLA, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 giu 2026 · NCT05124912

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

In reclutamentoFase 2
  • VA Greater Los Angeles Healthcare System, Los Angeles
Età 18 e oltre · Uomini · Aggiornato il 15 giu 2026 · NCT05422911

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

In reclutamentoFase 1
  • The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 giu 2026 · NCT06917079

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

In reclutamentoFase 3
  • UCLA Hematology Oncology Santa Monica, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 mag 2026 · NCT06757634

Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

In reclutamentoFase 2/3
  • Helios Clinical Research, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 mag 2026 · NCT06697301

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

In reclutamentoFase 1/2
  • USC Norris Comprehensive Cancer Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 apr 2026 · NCT06413680

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

In reclutamentoFase 1/2
  • Cedars-Sinai Medical Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 apr 2026 · NCT07020221

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

In reclutamentoFase 2/3
  • USC Norris Comprehensive Cancer Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 apr 2026 · NCT06947928

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

In reclutamentoFase 3
  • University of California Los Angeles, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 apr 2026 · NCT06064877

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

In reclutamentoFase 2/3
  • The Angeles Clinic and Research Institute, Los Angeles
  • University of California Los Angeles, Los Angeles
Tutte le età · Tutti i sessi · Aggiornato il 2 apr 2026 · NCT06581406

Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)

In reclutamentoFase 2
  • USC/Norris Cancer Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 31 mar 2026 · NCT06634875

A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors

In reclutamentoFase 1
  • USC Norris Comprehensive Cancer Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 20 mar 2026 · NCT05948865

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

In reclutamentoFase 1
  • UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Età da 18 a 75 · Tutti i sessi · Aggiornato il 17 mar 2026 · NCT04119024

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

In reclutamentoFase 1/2
  • Los Angeles General Medical Center, Los Angeles
  • USC/Norris Comprehensive Cancer Center, Los Angeles
Età da 18 a 99 · Tutti i sessi · Aggiornato il 10 mar 2026 · NCT04333706

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

In reclutamento
  • Cedars-Sinai Medical Center, Los Angeles
Età da 18 a 99 · Tutti i sessi · Aggiornato il 20 feb 2026 · NCT04907643

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

In reclutamentoFase 1
  • USC - Norris Comprehensive Cancer Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 13 feb 2026 · NCT06778863

Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen

In reclutamentoFase 3
  • Usc Norris Comprehensive Cancer Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 feb 2026 · NCT06127407

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

In reclutamentoFase 1
  • USC Norris Comprehensive Cancer Center, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2025 · NCT05808634

A Study of NX-1607 in Adults With Advanced Malignancies

In reclutamentoFase 1
  • University of Southern California, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 9 set 2025 · NCT05107674

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

In reclutamentoFase 1/2
  • University of Southern California, Los Angeles
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2025 · NCT05394103

Studi su Cancro metastatico in altre città

Altri studi a Los Angeles

Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.